Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).

Read more about Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

In this week’s patent news: Patent Office notifies Supreme Court’s order on Extensions of Timelines; Patent office announces JPO/IPR Training Course FY 2021; BananaIP and...

Read more about Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more

In this week’s patent news: Natco files compulsory license request for Baricitinib; USA approves temporary patent waiver; EU critical of US proposal for patent waiver,...

Read more about Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more